Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
63
TYRA Quote, Financials, Valuation and Earnings
Last price:
$39.63
Seasonality move
:
-0.15%
Day range:
$37.10 - $40.00
52-week range:
$6.42 - $40.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.52x
Volume:
1M
Avg. volume:
1.2M
1-year change:
357.92%
Market cap:
$2.2B
Revenue:
--
EPS (TTM):
-$2.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TYRA
Tyra Biosciences, Inc.
|
-- | -$0.59 | -- | -24.07% | $51.07 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$13.8M | -$1.78 | 56.38% | -15.51% | $43.75 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$754.8M | $1.00 | 3.04% | 4.71% | $88.87 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$198.2M | -$0.78 | 51.16% | -16.46% | $96.81 |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$0.66 | 315.28% | -8.42% | $60.79 |
|
TRDA
Entrada Therapeutics, Inc.
|
$2.9M | -$1.02 | -83.77% | -135.95% | $20.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TYRA
Tyra Biosciences, Inc.
|
$39.61 | $51.07 | $2.2B | -- | $0.00 | 0% | -- |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$35.20 | $43.75 | $2.1B | 3.91x | $0.00 | 0% | 38.89x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$55.50 | $88.87 | $10.3B | 31.15x | $0.00 | 0% | 3.33x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$74.79 | $96.81 | $12.3B | -- | $0.00 | 0% | 13.08x |
|
SYRE
Spyre Therapeutics, Inc.
|
$47.58 | $60.79 | $3.6B | -- | $0.00 | 0% | 701.12x |
|
TRDA
Entrada Therapeutics, Inc.
|
$13.15 | $20.00 | $491.1M | 7.16x | $0.00 | 0% | 20.88x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TYRA
Tyra Biosciences, Inc.
|
2.19% | -1.931 | 0.41% | 14.15x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.26% | 0.320 | 2.53% | 10.52x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.55% | -0.343 | 5.63% | 3.25x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
84.24% | 2.976 | 20.24% | 3.51x |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -1.674 | -- | 12.89x |
|
TRDA
Entrada Therapeutics, Inc.
|
14.26% | -2.167 | 12.94% | 12.17x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TYRA
Tyra Biosciences, Inc.
|
-$132K | -$36.5M | -38.98% | -39.76% | -- | -$23.7M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$16.8M | -$121.6M | -29.08% | -30.11% | -608.9% | -$97.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$614.5M | $99.8M | 5.33% | 5.89% | 11.16% | $56.6M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$191.1M | -$215M | -14.26% | -67.97% | -105.91% | -$160.4M |
|
SYRE
Spyre Therapeutics, Inc.
|
-- | -$57.2M | -25.86% | -25.86% | -- | -$44.6M |
|
TRDA
Entrada Therapeutics, Inc.
|
$413K | -$42.2M | -33.48% | -38.39% | -3249.27% | -$32M |
Tyra Biosciences, Inc. vs. Competitors
-
Which has Higher Returns TYRA or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of -541.09%. Tyra Biosciences, Inc.'s return on equity of -39.76% beat Agios Pharmaceuticals, Inc.'s return on equity of -30.11%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.57 $265M AGIOAgios Pharmaceuticals, Inc.84.25% -$1.85 $1.2B -
What do Analysts Say About TYRA or AGIO?
Tyra Biosciences, Inc. has a consensus price target of $51.07, signalling upside risk potential of 28.93%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $43.75 which suggests that it could grow by 17.9%. Given that Tyra Biosciences, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Tyra Biosciences, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 AGIOAgios Pharmaceuticals, Inc.6 3 0 -
Is TYRA or AGIO More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.263%.
-
Which is a Better Dividend Stock TYRA or AGIO?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or AGIO?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $20M. Tyra Biosciences, Inc.'s net income of -$33.8M is higher than Agios Pharmaceuticals, Inc.'s net income of -$108M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 38.89x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$33.8M AGIOAgios Pharmaceuticals, Inc.38.89x 3.91x $20M -$108M
-
Which has Higher Returns TYRA or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of -5.2%. Tyra Biosciences, Inc.'s return on equity of -39.76% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.57 $265M BMRNBioMarin Pharmaceutical, Inc.68.65% -$0.24 $6.7B -
What do Analysts Say About TYRA or BMRN?
Tyra Biosciences, Inc. has a consensus price target of $51.07, signalling upside risk potential of 28.93%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 60.13%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Tyra Biosciences, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Tyra Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 BMRNBioMarin Pharmaceutical, Inc.14 5 0 -
Is TYRA or BMRN More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.293, suggesting its less volatile than the S&P 500 by 70.697%.
-
Which is a Better Dividend Stock TYRA or BMRN?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or BMRN?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $895M. Tyra Biosciences, Inc.'s net income of -$33.8M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 3.33x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$33.8M BMRNBioMarin Pharmaceutical, Inc.3.33x 31.15x $895M -$46.6M
-
Which has Higher Returns TYRA or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of -112.81%. Tyra Biosciences, Inc.'s return on equity of -39.76% beat Ionis Pharmaceuticals, Inc.'s return on equity of -67.97%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.57 $265M IONSIonis Pharmaceuticals, Inc.94.14% -$1.41 $3.1B -
What do Analysts Say About TYRA or IONS?
Tyra Biosciences, Inc. has a consensus price target of $51.07, signalling upside risk potential of 28.93%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $96.81 which suggests that it could grow by 29.44%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Tyra Biosciences, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Tyra Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is TYRA or IONS More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.146%.
-
Which is a Better Dividend Stock TYRA or IONS?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or IONS?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $203M. Tyra Biosciences, Inc.'s net income of -$33.8M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$229M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 13.08x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$33.8M IONSIonis Pharmaceuticals, Inc.13.08x -- $203M -$229M
-
Which has Higher Returns TYRA or SYRE?
Spyre Therapeutics, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of --. Tyra Biosciences, Inc.'s return on equity of -39.76% beat Spyre Therapeutics, Inc.'s return on equity of -25.86%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.57 $265M SYRESpyre Therapeutics, Inc.-- -$0.69 $715.2M -
What do Analysts Say About TYRA or SYRE?
Tyra Biosciences, Inc. has a consensus price target of $51.07, signalling upside risk potential of 28.93%. On the other hand Spyre Therapeutics, Inc. has an analysts' consensus of $60.79 which suggests that it could grow by 27.76%. Given that Tyra Biosciences, Inc. has higher upside potential than Spyre Therapeutics, Inc., analysts believe Tyra Biosciences, Inc. is more attractive than Spyre Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 SYRESpyre Therapeutics, Inc.15 0 0 -
Is TYRA or SYRE More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spyre Therapeutics, Inc. has a beta of 2.931, suggesting its more volatile than the S&P 500 by 193.131%.
-
Which is a Better Dividend Stock TYRA or SYRE?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spyre Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. Spyre Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or SYRE?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than Spyre Therapeutics, Inc. quarterly revenues of --. Tyra Biosciences, Inc.'s net income of -$33.8M is higher than Spyre Therapeutics, Inc.'s net income of -$51.8M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while Spyre Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 701.12x for Spyre Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$33.8M SYRESpyre Therapeutics, Inc.701.12x -- -- -$51.8M
-
Which has Higher Returns TYRA or TRDA?
Entrada Therapeutics, Inc. has a net margin of -- compared to Tyra Biosciences, Inc.'s net margin of -3014.94%. Tyra Biosciences, Inc.'s return on equity of -39.76% beat Entrada Therapeutics, Inc.'s return on equity of -38.39%.
Company Gross Margin Earnings Per Share Invested Capital TYRATyra Biosciences, Inc.-- -$0.57 $265M TRDAEntrada Therapeutics, Inc.31.79% -$0.94 $357.1M -
What do Analysts Say About TYRA or TRDA?
Tyra Biosciences, Inc. has a consensus price target of $51.07, signalling upside risk potential of 28.93%. On the other hand Entrada Therapeutics, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 52.09%. Given that Entrada Therapeutics, Inc. has higher upside potential than Tyra Biosciences, Inc., analysts believe Entrada Therapeutics, Inc. is more attractive than Tyra Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TYRATyra Biosciences, Inc.9 0 0 TRDAEntrada Therapeutics, Inc.8 0 0 -
Is TYRA or TRDA More Risky?
Tyra Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Entrada Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TYRA or TRDA?
Tyra Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tyra Biosciences, Inc. pays -- of its earnings as a dividend. Entrada Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TYRA or TRDA?
Tyra Biosciences, Inc. quarterly revenues are --, which are smaller than Entrada Therapeutics, Inc. quarterly revenues of $1.3M. Tyra Biosciences, Inc.'s net income of -$33.8M is higher than Entrada Therapeutics, Inc.'s net income of -$39.2M. Notably, Tyra Biosciences, Inc.'s price-to-earnings ratio is -- while Entrada Therapeutics, Inc.'s PE ratio is 7.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tyra Biosciences, Inc. is -- versus 20.88x for Entrada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TYRATyra Biosciences, Inc.-- -- -- -$33.8M TRDAEntrada Therapeutics, Inc.20.88x 7.16x $1.3M -$39.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
